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Background: Several studies have shown that the ethanol-derived metabolite salsolinol
(SAL) can activate the mesolimbic system, suggesting that SAL is the active molecule
mediating the rewarding effects of ethanol. In vitro and in vivo studies suggest that
SAL exerts its action on neuron excitability through a mechanism involving opioid
neurotransmission. However, there is no direct pharmacologic evidence showing that
SAL activates opioid receptors.
Methods: The ability of racemic (R/S)-SAL, and its stereoisomers (R)-SAL and (S)-SAL,
to activate the µ-opioid receptor was tested in cell-based (light-emitting) receptor
assays. To further characterizing the interaction of SAL stereoisomers with the µ-opioid
receptor, a molecular docking study was performed using the crystal structure of the
µ-opioid receptor.
Results: This study shows that SAL activates the µ-opioid receptor by the classical G
protein-adenylate cyclase pathway with an half-maximal effective concentration (EC50)
of 2 × 10−5 M. The agonist action of SAL was fully blocked by the µ-opioid antagonist
naltrexone. The EC50 for the purified stereoisomers (R)-SAL and (S)-SAL were 6 × 10−4
M and 9 × 10−6 M respectively. It was found that the action of racemic SAL on the
µ-opioid receptor did not promote the recruitment of β-arrestin. Molecular docking
studies showed that the interaction of (R)- and (S)-SAL with the µ-opioid receptor is
similar to that predicted for the agonist morphine.
Conclusions: It is shown that (R)-SAL and (S)-SAL are agonists of the µ-opioid
receptor. (S)-SAL is a more potent agonist than the (R)-SAL stereoisomer. In silico
analysis predicts a morphine-like interaction between (R)- and (S)-SAL with the µ-opioid
receptor. These results suggest that an opioid action of SAL or its enantiomers is
involved in the rewarding effects of ethanol.
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INTRODUCTION
The mechanisms underlying the addictive properties of ethanol
are still not fully understood since specific molecular targets
explaining its pharmacological actions have not yet been
identified. Unlike other drugs of abuse such as morphine,
cocaine or nicotine that elicit their effects at micromolar blood
concentrations (10−6 M; Jeffcoat et al., 1989; Glare and Walsh,
1991; Benowitz and Jacob, 1993), the pharmacological effects
of ethanol are evident only at millimolar blood levels (10−3 M;
Holford, 1987). The low potency of ethanol could be attributed
to its molecular simplicity, hampering its binding with high
affinity to any type of receptor. Nevertheless, a number of
studies have shown that acetaldehyde, the primary metabolite
of ethanol in the brain, is self-administered intracranially by
rats at micromolar concentrations showing strong motivational
and reinforcing effects (Rodd et al., 2005). Indeed, ethanol
metabolism to acetaldehyde in the brain is required to exert
ethanol’s reinforcing actions (Karahanian et al., 2011, 2015;
Quintanilla et al., 2012; Israel et al., 2015; Peana et al., 2016).
In the brain, ethanol-derived acetaldehyde can condense
non-enzymatically with dopamine to generate racemic
(R/S)-salsolinol (SAL, 1-methyl-1,2,3,4-tetrahydro-6,7-
dihydroxy-isoquinoline; Melchior and Collins, 1982). Studies
by Rommelspacher et al. (1995) showed that levels of SAL
in the blood of alcoholics were higher than those found in
non-alcoholic individuals. The exposure of healthy individuals
to an acute dose of ethanol results in an increase of SAL
concentrations in blood and urine (Haber et al., 1996). Animal
studies have shown that chronic ethanol administration to rats
results in a significant increase of SAL levels in dopamine-rich
areas of the brain such as striatum, limbic forebrain and
hypothalamus (Sjöquist et al., 1982; Matsubara et al., 1987),
yielding increased amounts of SAL (Rojkovicova et al., 2008).
Behavioral studies performed in rats have shown that SAL
administration results in major increases in voluntary ethanol
intake (Myers and Melchior, 1977; Quintanilla et al., 2014,
2016), locomotor activity (Hipólito et al., 2010; Quintanilla
et al., 2014) and conditioned place preference (Matsuzawa et al.,
2000; Quintanilla et al., 2014). Microdialysis studies have shown
that microinjections of SAL into the ventral tegmental area
(VTA) of rats result in an increased release of dopamine in the
nucleus accumbens (Deehan et al., 2013), a common hallmark
shared by different drugs of abuse, including ethanol (Di Chiara
and Imperato, 1988). Furthermore, SAL is self-administered
intracranially by rats at concentrations ranging from 0.03 µM
to 0.3 µM (Rodd et al., 2008; Deehan et al., 2013). These
concentrations are 10–100 times lower than that required for
acetaldehyde self-administration, suggesting that SAL is an active
molecule involved in the rewarding effects of ethanol. Indeed,
recent electrophysiology studies by Melis et al. (2015) showed
that inhibition of dopamine synthesis by a tyrosine hydroxylase
inhibitor fully abolishes the ability of ethanol (100 mM) and
acetaldehyde (10 nM) to stimulate VTA dopaminergic neurons.
Experimental evidence suggests that the activating/rewarding
properties of SAL are mediated by mechanisms involving
µ-opioid receptors, although the levels at which this effect occurs
is not known. Studies by Matsuzawa et al. (2000) showed that
place preference conditioning elicited by SAL is significantly
attenuated by the concomitant administration of the selective
µ-opioid receptor antagonist β-funaltrexamine. Similar results
were obtained by Hipólito et al. (2010), who found that the
administration of β-funaltrexamine reduces the increase in
locomotor activity elicited by the intra-VTA administration
of SAL to rats. Recent studies by Quintanilla et al. (2014)
showed that repeated systemic administration of racemic SAL
(10 mg/kg, i.p.) led to a marked increase in voluntary ethanol
intake in rats. This sensitization to ethanol intake was fully
blocked by the concomitant intra-VTA administration of the
opioid antagonist naltrexone, suggesting that the VTA is the
primary site of action of SAL and its mechanism of action
mediated by opioid receptors. It has been proposed that SAL
could bind to µ-opioid receptors on GABAergic neurons of
the VTA, inducing hyperpolarization, resulting in disinhibition
and therefore activation of nearby dopaminergic neurons (Xie
et al., 2013), resembling the action of opioid drugs (Johnson
and North, 1992). In line with this view, electrophysiological
studies performed in VTA-containing brain slices showed
that SAL increased the firing of dopamine neurons by a
µ-opioid/GABAergic combined mechanism, since the activating
effects of SAL were blocked by both the µ-opioid antagonist
naltrexone and the GABAA receptor antagonist gabazine (Xie
et al., 2012).
Despite early reports suggesting that SAL (10−8 to 10−3 M)
can bind to opioid receptors (Fertel et al., 1980; Lucchi et al.,
1982), there are no specific studies aimed at determining the
intrinsic activity of SAL on µ-opioid receptors. We report
here a light emission cell-based receptor assays describing
the effect of SAL on µ-opioid receptors, based on the
activation of the canonical signaling pathway associated to
G protein. We also assessed the capacity of SAL to activate
the G protein-independent signaling pathway associated with
β-arrestin recruitment. We extended these in vitro studies to
assess the action of the SAL stereoisomers (R)-SAL and (S)-SAL.
To further understand the interaction of SAL with the µ-opioid
receptor, we also investigated on molecular docking analyses,
comparing (R)-SAL vs. (S)-SAL on their ability to bind to
the active site of the mouse µ-opioid receptor, whose crystal
structure was recently published (Huang et al., 2015).
MATERIALS AND METHODS
Materials
Racemic SAL was purchased from Santa Cruz Biotechnology
(Dallas, TX, USA), naltrexone was from Alfa Aesar (Ward Hill,
MA, USA). Ammonium acetate was from Merck (Darmstadt,
Germany) and triethylamine was from Sigma (St. Louis, MO,
USA).
Separation and Purification of (R) and
(S)-Salsolinol
(R)-SAL and (S)-SAL were separated from the racemic solution
by high-pressure liquid chromatography (HPLC) as described
previously (Quintanilla et al., 2016). Briefly, a solution of (R/S)-
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SAL was injected into a NUCLEODEX β-cyclodextrin-modified
column (Macherey-Nagel, Düren, Germany) kept at 20◦C. The
column was coupled to a LC-4C BAS amperometric detector
(ED) set to a potential of 700 mV. The mobile phase, composed
of volatile 100 mM ammonium acetate and 10 mM triethylamine
(pH 4.0), was injected at a flow rate of 0.40 mL/min. Previous
reports indicate that (S)-SAL enantiomer is the first to be eluted
following similar chromatographic conditions (Deng et al., 1995;
Naoi et al., 1996; Tóth et al., 2001; Quan et al., 2005; Rojkovicova
et al., 2008; Lee et al., 2010). Once (R/S)-SAL was injected
into the HPLC, the enantiomers were separated and collected
according to their corresponding elution time (electrochemical
detector disconnected). To check their purity, samples were
reinjected onto the HPLC system. Each purified fraction was
lyophilized at −54◦C for 9 h for mobile phase elimination
and dissolved in HCl 10−5 M, (pH 5.0). The concentration
of purified samples was determined either by HPLC-ED or
by absorbance at 290 nm, using a calibration curve with
(R/S)-SAL as a standard. Samples were stored at−20◦C in amber
microtubes.
Activation of µ-Opioid Receptors through
the Gi Protein-Signaling Pathway
The intrinsic activity of the ligands was studied using
commercially cell-based assays, composed by recombinant
CHO-K1 cells that overexpress only the human µ-opioid
receptor, detecting the levels of second messengers that reflect
the activation of this receptor. To assess the activation of the
µ-opioid receptor through the recruitment of G protein signaling
pathway, we used the cyclic adenosine monophosphate (cAMP)
Hunterr eXpress G protein-coupled receptor (GPCR) Assay
(DiscoverX, Freemont, CA, USA) following the manufacturer
instructions. In this system, the endogenous cAMP competes
with an exogenous cAMP coupled to a truncated β-galactosidase
fragment (provided by the assay) for binding to a cAMP
antibody. Only the unbound exogenous cAMP-β-galactosidase
fragment binds to a complementary β-galactosidase fragment to
form the active enzyme. The activity of β-galactosidase, measured
by adding a chemiluminescent substrate, reflects proportionally
the levels of cellular cAMP. (R)-SAL, (S)-SAL and (R/S)-
SAL, dissolved in HCl 10−5 M, (pH 5.0) and including the
adenylate cyclase activator forskolin (20 µM), were incubated
at concentrations ranging from 1 × 10−8 M to 1 × 10−3 M
with the CHO-K1 cells for 30 min. Morphine was incubated
at concentrations ranging from 3 × 10−9 M to 1 × 10−4 M
under the same conditions. Control cells were incubated only
with forskolin. The resulting luminescence was measured with
a microplate reader Synergy HT (Biotek, Winooski, VT, USA)
or a microplate reader SpectraMax M3 (Molecular Devices,
Sunnyvale, CA, USA). The experiment was repeated three times
in duplicate for (R)-SAL, (S)-SAL and (R/S)-SAL and two times
in duplicate for morphine.
In a subsequent experiment, the activation of the µ-opioid
receptor by racemic SAL (150µM) was studied after the addition
of different concentrations (3 × 10−10 M to 10−5 M) of the
antagonist naltrexone to the recombinant cells, dissolved in assay
buffer, 30 min before to the addition of SAL. All measurements
were expressed as relative luminescence to the controls with no
ligand added. Each concentration of naltrexone was assayed once
in duplicate. The antagonistic action of naltrexone was selective
for µ-opioid receptor since the recombinant cells used in the
study only overexpress this type of opioid receptor.
Activation of µ-Opioid Receptors through
the β-Arrestin Signaling Pathway
To assess the activation of the µ-opioid receptor through
the recruitment of the β-arrestin signaling pathway, we used
a PathHunterr eXpress β-Arrestin GPCR chemiluminescent
assay (DiscoverX) following the manufacturer instructions.
In this system, the human µ-opioid receptor is fused to
a small fragment of β-galactosidase (PK) and co-expressed
in cells expressing a fusion protein of β-arrestin and the
complementary fragment of β-galactosidase (EA). Activation
of the µ-opioid receptor stimulates binding of β-arrestin to
the PK-tagged receptor allowing the complementation of the
two enzyme fragments of β-galactosidase. This action leads to
an activation of the enzyme that can be measured using a
chemiluminescent reagent resulting in luminescence, which is
proportional to the recruitment of β-arrestin. DADLE ([D-Ala2,
D-Leu5]-Enkephalin), (R/S)-SAL and morphine (dissolved in
HCl 10−5 M, pH 5.0), were incubated at concentrations
ranging from 1 × 10−8 to 1 × 10−3 M with the cells
for 30 min. The experiment was repeated three times in
duplicate for each concentration of ligand. The resulting
luminescence was determined with a microplate reader Synergy
HT (Biotek).
Molecular Docking
Molecular docking simulations were performed using the
crystal structure of the mouse µ-opioid receptor bound to the
morphinan high-affinity agonist BU72 (Neilan et al., 2004),
obtained from the protein data bank as a PDB file (ID: 5C1M;
Huang et al., 2015). For the simulations, water molecules near the
receptor were conserved, but BU72 and any other co-crystallized
molecules were removed. After that, polar hydrogens were
added to the protein coordinates (not resolved in the crystal
structure). The studied molecules, morphine, (R)-SAL and
(S)-SAL, were prepared and optimized to their energy minima
using SPARTAN 10. Docking simulations were performed
using Autodock Vina (Trott and Olson, 2010), which renders
the ligand fully flexible, while to the target protein a rigid
structure. The search space was 24 Å3 around a side-chain
oxygen of Asp147, regarded as a critical residue for the binding
of ligands to this receptor (Li et al., 1999; Manglik et al.,
2012; Shim et al., 2013; Huang et al., 2015). The searching
exhaustiveness was 800 (default 8). Ligand-protein interactions
analyses and 3D figures were prepared using PyMOL (DeLano,
2002).
Statistical Analyses
The half-maximal effective concentration (EC50) for each ligand
and half-maximal inhibitory concentration (IC50) for naltrexone
in the antagonist assay were determined by correlating the
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data to a non-linear equation of ligand concentration (log M)
vs. response by three parameters. The fitting of the data to
the correlation was assessed by its corresponding coefficient
of determination (R2), using GraphPad Prism (San Diego, CA,
USA).
RESULTS
Activation of µ-Opioid Receptors by
Racemic SAL through the Gi
Protein-Signaling Pathway
To study the capacity of SAL to activate the µ-opioid receptor,
we used a commercial assay based in CHO-K1 cells expressing
the human µ-opioid receptor. Since the µ-opioid receptor
is coupled to an inhibitory G protein (Gi), its activation by
an agonist results in a reduction of intracellular levels of
cAMP. Figure 1 shows the relative intracellular cAMP levels,
measured as a chemiluminescent signal, elicited by the action of
different concentrations of racemic SAL and theµ-opioid agonist
morphine. Results showed that SAL is effective to activate the
µ-opioid receptor through the G protein-signaling pathway but
at lower potency compared to morphine. An EC50 for racemic
SAL was 2 × 10−5 M (R2 = 0.86), while the EC50 for morphine
was 4× 10−9 M (R2 = 0.96).
Following the pharmacodynamic characterization of SAL on
the µ-opioid receptor, the effect of different concentrations
(1 × 10−5 M to 3 × 10−10 M) of the antagonist naltrexone was
determined on the activation of the µ-opioid receptor elicited
by racemic SAL at a concentration of 1.5 × 10−4 M. As it is
seen in Figure 1, this SAL concentration is able to elicit 80% of
FIGURE 1 | Salsolinol (SAL) acts as an agonist of µ-opioid receptors.
Functional assay of µ-opioid receptor dose-response activation by morphine
and racemic (R/S)-SAL. Each ligand was assayed three times in duplicate
using concentrations ranged from 1 × 10−8 M to 1 × 10−3 for (R/S)-SAL, and
3 × 10−9 M to 1 × 10−4 M for morphine. Values are expressed as the means
of cyclic adenosine monophosphate (cAMP) levels (percentage relative de
control) ± SEM. The luminescence is proportional to the intracellular cAMP
levels (induced by forskolin); therefore, a decrease in cAMP levels signals the
activation of the µ-opioid receptor, which is coupled to a inhibitory G protein
(Gi). Half-maximal effective concentration (EC50) corresponds to the
concentration of ligand eliciting 50% of the maximal response. (R/S)-SAL
curve: degrees of freedom, 26 (four points excluded as outliers, at
[Ligand](log, M) = −3, −3.5, −7, −7.5); R2 = 0.8809. Morphine curve:
degrees of freedom, 17; R2 = 0.8825.
the maximal response in this cell-based assay. Figure 2 shows
that naltrexone antagonizes, in a dose-dependent fashion, the
ability of racemic SAL to activate the µ-opioid receptor and to
reduce intracellular cAMP levels. A complete antagonism of the
SAL action is reached at naltrexone concentrations of 10−8 M. A
non-linear fit analysis of the data revealed that naltrexone showed
an IC50 of 1× 10−9 M (R2 = 0.85).
Separation and Purification of (R) and
(S)-Salsolinol
The enantiomers (R)-SAL and (S)-SAL were separated and
purified from racemic (R/S)-SAL by HPLC. Figure 3A shows
the retention time of the enantiomers: (S)-SAL = 6.7 min
and (R)-SAL = 8.3 min, in chromatographs showing equal
areas for (S)-SAL and (R)-SAL in a sample containing
racemic (R/S)-SAL. Figures 3B,C show the chromatograms
obtained for purified (S)-SAL and (R)-SAL respectively. The
quantification of the area under the curve for (R)-SAL
and (S)-SAL showed that both stereoisomers were 99%
pure.
Activation of µ-Opioid Receptors by (R)-
and (S)-SAL through the Gi
Protein-Signaling Pathway
The capacity of the purified enantiomers (R)-SAL and (S)-SAL
to activate the µ-opioid receptor (G protein signaling
pathway) was assayed using the same methodology used
for assaying racemic SAL. Figure 4 shows the changes in
cAMP levels, measured as a chemiluminescent signal, elicited
FIGURE 2 | The action of racemic SAL is fully blocked by the µ-opioid
receptor antagonist naltrexone. Levels of cAMP (percentage relative to
control) detected after incubation with racemic (R/S)-SAL 150 µM in the
presence of different concentrations of the antagonist naltrexone (1 × 10−5 M
to 3 × 10−10 M) are shown. The activation of the µ-opioid receptor by the
addition of the (R/S)-SAL 150 µM was assayed 30 min after the addition of
the antagonist. This concentration of (R/S)-SAL elicits 80% of the maximal
response of the system. The antagonism of the inhibitory action of SAL on
µ-opioid receptor results in an increase of intracellular cAMP levels. The
shown results are from one experiment performed in duplicate and each point
represents one of the two replicates for each concentration of antagonist.
Half-maximal inhibitory concentration (IC50) corresponds to the concentration
of antagonist reducing 50% the maximal response to the agonist. Degrees of
freedom, 7; R2 = 0.8550.
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FIGURE 3 | Purification of (R)-SAL and (S)-SAL from racemic
(R/S)-SAL. High-pressure liquid chromatography (HPLC) chromatographs of
(A) racemic (R/S)-SAL 1 × 10−2 M (corresponding to 5 × 10−3 M of each
enantiomer), (B) purified (S)-SAL 4 × 10−3 M (non-detectable levels of
(R)-SAL) and (C) purified (R)-SAL 3 × 10−3 M (non-detectable levels of
(S)-SAL). The volume of each sample was 50 µL, and the flow rate was
0.8 ml/min. The concentrations of the enantiomers in the purified solutions
were determined using racemic (R/S)-SAL as standard.
by different concentrations (10−3 M to 10−8 M) of (R)-SAL
and (S)-SAL. Results showed that both enantiomers were
effective in activating the µ-opioid receptor, displaying
a similar efficacy (capacity to reduce intracellular cAMP
levels) but a higher potency (lower concentration needed
to activate the receptor) for (S)-SAL compared to (R)-SAL.
The EC50 for (S)-SAL (9 × 10−6 M, R2 = 0.81) was 50 times
lower than the EC50 calculated for (R)-SAL (6 × 10−4 M,
R2 = 0.71).
FIGURE 4 | (R)-SAL and (S)-SAL stereoisomers act as agonists on
µ-opioid receptor. Functional assay of the µ-opioid receptor dose-response
activation by (R)-SAL and (S)-SAL. Each ligand was assayed three times, each
concentration, in duplicate using concentrations ranging from 1 × 10−8 M to
1 × 10−3 M. Values are expressed as mean cAMP levels (percentage relative
de control) ± SEM. The luminescence is proportional to the intracellular cAMP
levels (induced by forskolin); therefore, a decrease in cAMP levels signals the
activation of the µ-opioid receptor, which is coupled to a Gi protein. EC50
corresponds to the concentration of ligand eliciting 50% of the maximal
response. (R)-SAL curve: degrees of freedom, 28 (two points excluded as
outliers, at [Ligand](log, M) = −7, −7.5); R2 = 0.8267. (S)-SAL curve: degrees
of freedom, 28 (two points excluded as outliers, at [Ligand](log, M) = −7,
−7.5); R2 = 0.9072.
Activation of µ-Opioid Receptors by
Racemic SAL through the β-Arrestin
Signaling Pathway
Several opioid agonists can activate with different efficacies
the G protein-independent signaling pathway led by the
recruitment of β-arrestin. This action of opioid agonists has been
correlated with their capacity to induce internalization/recycling
of µ-opioid receptors (see Williams et al., 2013). For this
reason, we studied the effect of different concentrations of
racemic SAL and the µ-opioid agonists DADLE and morphine
on CHO-K1 cells engineered to express the µ-opioid receptor
and to detect the recruitment of β-arrestin in response to such
agonists.
Figure 5 shows that racemic SAL was, at all tested
concentrations, unable to activate the β-arrestin signaling
pathway upon its binding on the µ-opioid receptor. In contrast,
DADLE showed the highest efficacy in activating the β-arrestin
signaling pathway on µ-opioid receptors, displaying an EC50 of
1 × 10−6 M (R2 = 0.98). Results also showed that morphine
activates the β-arrestin pathway upon its action on µ-opioid
receptors (EC50 = 2 × 10−6, R2 = 0.99) but displaying a lower
efficacy (50%) compared to DADLE. Since racemic SAL was
inactive on the β-arrestin signaling pathway, no studies with
(R)-SAL and (S)-SAL were conducted on β-arrestin recruitment
determination (see ‘‘Discussion’’ Section).
Molecular Docking of (R)-SAL and (S)-SAL
Enantiomers on the µ-Opioid Receptor
To further support the pharmacodynamics findings, molecular
docking analyses of morphine, (R)-SAL and (S)-SAL on the
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FIGURE 5 | The action of racemic SAL on the µ-opioid receptor does
not induce the recruitment of β-arrestin. The recruitment of β-arrestin in
response to morphine, [DAla2, D-Leu5]-Enkephalin (DADLE), and racemic SAL
was measured using a PathHunterr eXpress β-Arrestin G protein-coupled
receptor (GPCR) Assay (DiscoverX). DADLE and SAL were assayed in
duplicate using concentrations ranged within 1 × 10−9 to 1 × 10−4. Data for
morphine correspond to a single assay using concentrations ranged within
1 × 10−8 to 1 × 10−4 M for morphine. Values are expressed as the mean of
relative luminescence units (RLU) ± SEM. The luminescence is directly
proportional to the recruitment of β-arrestin. EC50 corresponds to the
concentration of ligand eliciting 50% of the maximal response. DADLE curve:
degrees of freedom, 18; R2 = 0.9838. Morphine curve: degrees of freedom, 6;
R2 = 0.9956.
coordinates of the binding site of the crystallized mouseµ-opioid
receptor were performed. Molecular docking studies started by
searching the spatial orientations (pose) of morphine, (R)-SAL
and (S)-SAL allowing: (i) the lowest minimum global energy
(score) of the ligand-receptor interaction; and (ii) the shorter
interaction distance (<4 Å) between the amino group of
the ligand and one of the side-chain oxygens of the Asp147
(N-Asp147) residue of the mouse µ-opioid receptor. This
interaction has been reported as an important feature for
opioid agonist activity (Li et al., 1999; Shim et al., 2013;
Huang et al., 2015). The scores and N-Asp147 distances
for nine different poses of morphine, (R)-SAL and (S)-SAL,
hierarchized according to their minimum score, are showed
in Table 1. Morphine displayed the lowest scores among the
three tested ligands, consistent with its higher potency for
the activation of the µ-opioid receptor. The docking scores
for SAL enantiomers were higher than those of by morphine;
however, slightly more favorable parameters were found for
(S)-SAL, which also showed better scores in all the poses than
(R)-SAL.
According to crystallographic studies reported by Shim
et al. (2013) and Huang et al. (2015), the residues of the
binding site of the µ-opioid receptor that are important for
the binding of agonists are Asp147, Tyr148, Met151, Val236,
Trp293, Ile296, His297, Val300, Trp318, Ile322 and Tyr326.
Figure 6 shows a molecular representation that highlights
the interactions of morphine, (R)-SAL and (S)-SAL, arranged
accordingly to their best pose, with the aforementioned amino
acidic residues. Figure 6B shows that morphine establishes a
salt bridge with Asp147 residue, forms hydrogen bonds with
Tyr148 and, through two water molecules, with His297. The
hydrophobic surface of morphine also binds to the hydrophobic
domain of the binding site, formed by Val300, Ile296 and Ile322.
Figures 6C,D show the molecular interactions predicted for
(R)-SAL and (S)-SAL, respectively. Since SAL enantiomers are
smaller molecules compared to morphine, they establish fewer
interactions with the receptor. Figure 6C shows that (R)-SAL
forms a salt bridge with Asp147 and, unlike morphine, the
orientation of its hydroxyl groups allows a direct hydrophobic
bond with His297. The hydrophobic surface of (R)-SAL also
interacts with Ile296 and Met151. Figure 6D shows that
the binding of (S)-SAL with the µ-opioid receptor is very
similar to the one showed by (R)-SAL, predicting interactions
with Asp147 and His297, and hydrophobic interactions with
Ile296 and Met151. However, the spatial orientation of the
methyl group, that defines the difference between the two SAL
enantiomers, contributes to an additional interaction of (S)-SAL
with Tyr148, which is not present in the simulation for the
(R)-SAL enantiomer.
DISCUSSION
The findings of this study support the hypothesis that
SAL acts as an agonist on the µ-opioid receptor. Overall,
we found that SAL is effective in activating the µ-opioid
receptor, showing an EC50 of 2 × 10−5 M. The agonist
activity of SAL on the µ-opioid receptor was fully blocked
by the µ-opioid antagonist naltrexone. Purified (R)-SAL and
(S)-SAL stereoisomers showed to be effective in activating
the µ-opioid receptor, displaying an EC50 of 6 × 10−4 M
and 9 × 10−6 M respectively. In agreement with these
results, molecular docking simulations predicted amorphine-like
interaction of (R)-SAL and (S)-SAL stereoisomers with the
µ-opioid receptor and a favored interaction for the (S)-SAL
stereoisomer.
The assays aimed at determining the intrinsic activity of SAL
showed that SAL is, as the full agonist morphine, effective in
activating the µ-opioid receptor, since both compounds display
nearly the same ability to inhibit the generation of intracellular
cAMP (as shown by a reduction in chemiluminiscence in
the present cell study). However, a marked difference was
observed between morphine and SAL on their potency, since
the EC50 of SAL was 5000-fold higher than that of morphine.
These results are in agreement with early radioligand binding
studies performed in rat striatum that showed that SAL can
displace the µ-opioid receptor agonist [met]-enkephalin with
an IC50 of 10 µM (1 × 10−5 M; Lucchi et al., 1982).
Recent electrophysiological studies in slices of posterior VTA
have shown that incubation with SAL (10−8 M to 10−6 M)
results in an increased firing of dopamine neurons. These
stimulatory effects of SAL on dopaminergic neurons are
abolished by the addition of naltrexone (Xie et al., 2012).
As proposed by Xie et al. (2013), SAL can indirectly activate
dopaminergic neurons in the VTA through the inhibition
of local GABAergic interneurons controlling the activity of
dopaminergic neurons, playing a key role on the rewarding
responses to SAL exposure. Recent in vivo studies have
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TABLE 1 | Docking parameters for morphine, (R)-SAL and (S)-SAL on the binding site of the mouse µ-opioid receptor.
Pose Morphine (R)-SAL (S)-SAL
Score (kcal/mol) N-O:Asp (Å) Score (kcal/mol) N-O:Asp (Å) Score (kcal/mol) N-O:Asp (Å)
1 −9.7 2.9 −7.5 3.0 −7.7 3.1
2 −8.7 6.1 −6.6 3.7 −6.7 5.5
3 −8.6 5.0 −6.5 6.2 −6.6 3.3
4 −8.4 7.2 −6.5 6.6 −6.5 5.7
5 −8.4 2.8 −6.5 6.3 −6.5 3.2
6 −8.1 5.5 −6.4 3.2 −6.4 8.4
7 −7.4 5.4 −6.4 6.0 −6.3 5.8
8 −6.8 7.2 −6.4 7.8 −6.3 7.6
9 −6.8 3.4 −6.2 8.0 −6.2 6.6
Docking scores and Ligand:N-O:Asp147 distances for the poses obtained for morphine, (R)-SAL and (S)-SAL on the binding site of the mouse µ-opioid receptor. The
table shows the scores and N-Asp147 distances for nine different poses of morphine, (R)-SAL, (S)-SAL hierarchized according to its minimum score. Poses and its
corresponding score were determined using the Autodock Vina software. Scores are expressed as kcal/mol. The predicted distances between the amino group of the
ligand and the α-carboxylic acid group of Asp147 (Ligand:N-O:Asp147) were determined using the PyMOL software. Ligand:N-O:Asp147 distances are expressed in
Angstroms.
determined the effects of SAL on the activity of dopaminergic
neurons in the VTA. Microdialysis studies in Wistar rats
have shown that the intra-VTA administration of SAL at
concentrations ranging within 10−7 M to 10−4 M can elicit a
marked increase of dopamine release in the nucleus accumbens
(Hipólito et al., 2011; Deehan et al., 2013). In addition,
the microinjection of SAL into the VTA of Wistar rats
at concentrations of 150 µM (15 × 10−5M) resulted in a
significant induction of locomotor activity (Hipólito et al.,
2010), conditioned place preference (Hipólito et al., 2011) and
ethanol intake (Quintanilla et al., 2014). These results show
that the concentrations at which SAL exerts its neurochemical
and behavioral effects in the VTA are similar to those able
to activate µ-opioid receptors in the present in vitro study
(EC50 = 2× 10−5 M).
In support of an agonistic action of SAL on µ-opioid
receptor, we found that the opioid antagonist naltrexone was
able to block almost completely the action of SAL with an
IC50 of 1 × 10−9 M. These values of IC50 for naltrexone are
in agreement with previous reports regarding the potency of
naltrexone as an antagonist of the µ-opioid receptor (Hahn
et al., 1985; Michel et al., 1985). These findings are also in
line with evidence showing that SAL effects are blocked by
µ-opioid receptor antagonists; e.g., conditioned place preference
(Matsuzawa et al., 2000); in vitro dopaminergic neurons
activation (Xie et al., 2012); dopamine release in the nucleus
accumbens (Hipólito et al., 2011); locomotor activation (Hipólito
et al., 2010) and increased ethanol consumption (Quintanilla
et al., 2014). An alternative mechanism by which SAL could
activate opioid transmission is by increasing the release of
endogenous opioids, such as β-endorphins. However, in vitro
studies on primary cultures of hypothalamic neurons have shown
that SAL, contrary to ethanol and acetaldehyde, is unable to
stimulate the secretion of β-endorphins (Reddy and Sarkar,
1993).
The classic signaling pathway associated to the agonist-
mediated activation of GPCRs involves the activation of the
corresponding heterotrimeric G protein and phosphorylation
of intracellular domains of the GPCR by G protein-coupled
receptor kinases (GRKs), which results in rapid desensitization
of GPCR to agonist action. Upon phosphorylation of GPCRs, a
conformational change greatly increases its affinity to β-arrestin,
a protein involved in receptor endocytosis processes and
activation of signaling pathways leading to different cellular
responses. After arrestin-mediated endocytosis, GPCR can be
either degraded or dephosphorylated and recycled to the
membrane surface as functional receptors (resensitization; See
Williams et al., 2013). For some GPCRs, including µ-opioid
receptors, there are agonists displaying a differential efficacy
(biased agonists) for recruiting β-arrestin proteins (Kenakin,
2011). In this study, we found that SAL acts as a biased
agonist on µ-opioid receptors, since it activates efficiently the
signaling pathway led by Gi protein, but not the recruitment
of β-arrestin. Interestingly, it has been proposed that agonists
that do not efficiently recruit β-arrestin, and therefore are not
able to promote an effective receptor endocytosis, may have an
increased potential to produce tolerance and dependence due to
a reduction of functional receptors (Whistler et al., 1999; Finn
and Whistler, 2001).
Taking into account the relatively low potency
showed by (R/S)-SAL in activating the µ-opioid receptor
(EC50 = 2 × 10−5 M), the question that arises is if the
concentration of SAL generated in the brain after ethanol
consumption is enough to generate an opioid response. Despite
several animal studies showing that chronic administration
of ethanol increases SAL levels in the hypothalamus and the
striatum (Sjöquist et al., 1982; Myers et al., 1985; Matsubara et al.,
1987), there are no studies showing the actual concentrations
of SAL generated in the brain by acute pharmacological doses
of ethanol. Brain microdialysis studies by Jamal et al. (2003)
showed that SAL is only detectable at nanomolar levels in the
striatum of rats whether ethanol administration is preceded
by a pre-treatment with the aldehyde dehydrogenase inhibitor
cyanamide, thus increasing acetaldehyde levels. These results
indicate that in vivo formation of SAL is highly dependent
on acetaldehyde levels, occurring only in dopamine-rich areas
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FIGURE 6 | (R)-SAL and (S)-SAL stereoisomers showed a morphine-like interaction with the binding site of the µ-opioid receptor. Molecular docking
analyses of morphine, (R)-SAL and (S)-SAL on the coordinates of the crystallized mouse µ-opioid receptor were performed. (A) Chemical structure of the molecules
studied: morphine, (R)-SAL and (S)-SAL. Hydroxyl groups are represented in red and amino groups are represented in blue. (B–D) Best docking fits of the three
studied molecules on the binding site of the µ-opioid receptor. The molecular surface of each molecule and the receptor is represented. A dotted line highlights the
main interactions of the ligands with the binding site of the µ-opioid receptor.
of the brain. Since catalase is the main enzyme responsible
for the metabolism of ethanol to acetaldehyde in the brain, a
heterogeneous distribution of catalase may allow the generation
of site-specific accumulations of acetaldehyde, yielding high
local concentrations of SAL (see Hipólito et al., 2007). In
agreement to this, studies by Brannan et al. (1981) showed that
catalase activity displays a regional distribution in the rat brain,
with high activity in the midbrain, a dopamine-rich area that
contains the VTA, deeply involved in the rewarding effects of
ethanol.
An alternative ethanol-independent route of SAL biosynthesis
in the brain has been proposed, involving the condensation
of dopamine with pyruvic acid to yield an intermediate
metabolite (salsolinol-1-carboxylic acid), which can be converted
in SAL through an enzymatic oxidative decarboxylation
(Naoi et al., 1996). However, experimental evidence regarding
the identity and properties of the enzymes involved in this
suggested biosynthetic pathway are still lacking.
The analysis of the actions of the (R) and (S) stereoisomers
of SAL showed that both molecules act as full agonists of the
µ-opioid receptor, with (S)-SAL being 50-fold more potent than
(R)-SAL. In line with a putative role of (S)-SAL on the actions of
ethanol, human studies by Rommelspacher et al. (1995) showed
that (S)-SAL levels in the plasma of alcoholics are 100-fold higher
than that in non-alcoholics, while (R)-SAL levels in the plasma
of alcoholics are only 2-fold higher than that in non-alcoholic
subjects. An animal study performed in alcohol-preferring P
rats showed that after 8 weeks of chronic ethanol consumption,
there was a 2-fold increase in (S)-SAL levels in the midbrain,
whereas a 1.6-fold increase was detected in (R)-SAL levels
(Rojkovicova et al., 2008). In contrast to these findings, a recent
behavioral study by Quintanilla et al. (2016) found that (R)-SAL
was the only enantiomer capable of inducing conditioned place
preference after its intracerebral infusion into the VTA of rats.
The reasons for these inconsistencies are unknown, but a possible
explanation would be the existence of different molecular targets
for (R)-SAL or its in vivo metabolism. Furthermore, there are
studies showing that SAL increases monoaminergic transmission
by inhibition of monoamine oxidase (MAO) activity in the brain
(Naoi et al., 2004) and by inhibition of monoamine reuptake
Frontiers in Behavioral Neuroscience | www.frontiersin.org 8 January 2017 | Volume 10 | Article 253
Berríos-Cárcamo et al. Salsolinol Action on µ-Opioid Receptors
(Alpers et al., 1975). Recent studies have also shown that SAL
could interact with other receptors as a monoamine derivative.
Electrophysiological studies by Xie and Ye (2012) showed that
the stimulant effect of SAL on dopaminergic neurons could be
attenuated by the D1 receptor antagonist, SKF83566. In fact,
intracerebral self-administration of SAL in alcohol-preferring
P rats is significantly reduced by the co-administration of
the dopamine D2,3 agonist quinpirole or the serotonin 5-HT3
antagonist ICS-205, 930 (Rodd et al., 2008). It is also possible that
both (R)-and (S)-SAL could present different affinities for other
opioid receptors such as the kappa and delta subtypes.
The higher potency showed by (S)-SAL is also supported
by molecular docking studies in which the binding of each
stereoisomer to the µ-opioid receptor was simulated and
analyzed. As shown in Table 1, in spite of the similarity
of the two enantiomers, (S)-SAL docking poses had lower
scores (predicted binding energy) than (R)-SAL in general,
and also when comparing best poses, which could account
for its higher experimental agonist potency. The low score
of (S)-SAL can be explained by the interaction of its chiral
methyl group with the receptor binding site, specifically with
the Tyr148 (Figure 6D), filling a cavity that is empty for (R)-
SAL (Figure 6C). To our knowledge SAL (179 Da) is the
smallest molecule described to date showing an opioid full
agonism. A possible limitation for the present docking study
is that computational simulations were performed using the
crystal structure of the mouse µ-opioid receptor instead of the
humanµ-opioid receptor used in the cell-based assays. However,
an overall comparison of the amino acid sequence shows a
94% of homology between the mouse and human receptors. A
near complete homology (>99%) is obtained if the comparison
only considers the domains comprising the binding site of the
receptor.
Overall, it is shown that racemic (R/S)-SAL and its
stereoisomers (R)-SAL and (S)-SAL are agonists of the µ-opioid
receptor, (S)-SAL being more potent than (R)-SAL. The in silico
study also shows that the interactions of (R)-SAL and (S)-SAL
with the binding-site of the µ-opioid receptor are analogous to
that shown by morphine. Further studies of the action of SAL
on µ-opioid receptor variants (e.g., A118G variant) or other
opioid receptor subtypes (e.g., delta or kappa) would provide
additional evidence of the role of SAL in the development of
alcohol addiction.
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